BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schnitzler F, Friedrich M, Stallhofer J, Schönermarck U, Fischereder M, Habicht A, Karbalai N, Wolf C, Angelberger M, Olszak T, Beigel F, Tillack C, Göke B, Zachoval R, Denk G, Guba M, Rust C, Grüner N, Brand S. Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort. PLoS One 2015;10:e0135807. [PMID: 26288187 DOI: 10.1371/journal.pone.0135807] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Safarpour AR, Shojaei-Zarghani S, Mehrabi M, Keshtkar AA, Oroojan AA, Sivandzadeh GR. Alterations in the Course of Inflammatory Bowel Disease Following Liver Transplantation: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2022:izac132. [PMID: 35779047 DOI: 10.1093/ibd/izac132] [Reference Citation Analysis]
2 Singh U, Singh B, Bellini MI. Immunosuppressive regimens and outcomes of inflammatory bowel disease patients requiring kidney transplantation. World J Transplant 2022; 12(2): 21-23 [DOI: 10.5500/wjt.v12.i2.21] [Reference Citation Analysis]
3 Meyer F, Weil-Verhoeven D, Prati C, Wendling D, Verhoeven F. Safety of biologic treatments in solid organ transplant recipients: A systematic review. Semin Arthritis Rheum 2021;51:1263-73. [PMID: 34507811 DOI: 10.1016/j.semarthrit.2021.08.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ribaldone DG, Imperatore N, Le Grazie M, Furfaro F, Balestrieri P, De Blasio F, Fagoonee S, Mosso E, Boano V, Reggio D, Sarli E, Castiglione F, Milla M, Vecchi M, Saracco GM, Salizzoni M, Romagnoli R, Fiorino G, Astegiano M; Italian Group for the study of Inflammatory Bowel Disease IG-IBD. Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study. Dig Liver Dis 2021;53:712-6. [PMID: 32972831 DOI: 10.1016/j.dld.2020.09.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Konduri A, Blake J, Aggarwal S. Crohn's disease with dilated cardiomyopathy in a child: An experience with heart transplantation. Pediatr Transplant 2021;25:e14027. [PMID: 33909325 DOI: 10.1111/petr.14027] [Reference Citation Analysis]
6 Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, Kumar D, Oberbauer R, Pascual J, Pilmore HL, Rodrigue JR, Segev DL, Sheerin NS, Tinckam KJ, Wong G, Knoll GA. KDIGO Clinical Practice Guideline on the evaluation and management of candidates for kidney transplantation. Transplantation. 2020;104:S11-S103. [PMID: 32301874 DOI: 10.1097/tp.0000000000003136] [Cited by in Crossref: 147] [Cited by in F6Publishing: 162] [Article Influence: 73.5] [Reference Citation Analysis]
7 Gioco R, Corona D, Ekser B, Puzzo L, Inserra G, Pinto F, Schipa C, Privitera F, Veroux P, Veroux M. Gastrointestinal complications after kidney transplantation. World J Gastroenterol 2020; 26(38): 5797-5811 [PMID: 33132635 DOI: 10.3748/wjg.v26.i38.5797] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
8 Hansrivijit P, Puthenpura MM, Thongprayoon C, Brar HS, Bathini T, Kovvuru K, Kanduri SR, Wijarnpreecha K, Cheungpasitporn W. Incidence and Impacts of Inflammatory Bowel Diseases among Kidney Transplant Recipients: A Meta-Analysis. Medical Sciences 2020;8:39. [DOI: 10.3390/medsci8030039] [Reference Citation Analysis]
9 Al Draiweesh S, Ma C, Alkhattabi M, McDonald C, Nguyen TM, Beaton M, Chande N, Colquhoun P, Feagan BG, Gregor JC, Khanna R, Marotta P, Ponich T, Quan D, Qumosani K, Sandhu A, Sey M, Skaro A, Teriaky A, Wilson A, Yan B, Brahmania M, Jairath V. Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:949-59. [PMID: 31665288 DOI: 10.1093/ibd/izz244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Grupper A, Schwartz D, Baruch R, Schwartz IF, Nakache R, Goykhman Y, Katz P, Lebedinsky A, Nachmany I, Lubezky N, Aouizerate J, Shashar M, Katchman H. Kidney transplantation in patients with inflammatory bowel diseases (IBD): analysis of transplantation outcome and IBD activity. Transpl Int. 2019;32:730-738. [PMID: 30793376 DOI: 10.1111/tri.13415] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
11 Sabino J, tenHove J, Torres J. Primary Sclerosing Cholangitis Overlapping with IBD. Biomarkers in Inflammatory Bowel Diseases 2019. [DOI: 10.1007/978-3-030-11446-6_16] [Reference Citation Analysis]
12 Kobiela J, Dobrzycka M, Danielewicz R, Jończyk J, Łachiński AJ, Śledziński Z, Dębska-Ślizień A. Colonoscopy as Part of Pre-Transplant Work-Up in Successful Kidney Transplant Candidates: Single-Center Experience and Review of Literature. Ann Transplant 2018;23:782-8. [PMID: 30409961 DOI: 10.12659/AOT.910658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Quinn CS, Jorgenson MR, Descourouez JL, Muth BL, Astor BC, Mandelbrot DA. Management of Tumor Necrosis Factor α Inhibitor Therapy After Renal Transplantation: A Comparative Analysis and Associated Outcomes. Ann Pharmacother 2019;53:268-75. [PMID: 30234366 DOI: 10.1177/1060028018802814] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
14 Altwegg R, Combes R, Laharie D, De Ledinghen V, Radenne S, Conti F, Chazouilleres O, Duvoux C, Dumortier J, Leroy V, Treton X, Durand F, Dharancy S, Nachury M, Goutorbe F, Lamblin G, Boivineau L, Peyrin-Biroulet L, Pageaux GP. Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series. Dig Liver Dis 2018;50:668-74. [PMID: 29655972 DOI: 10.1016/j.dld.2018.02.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
15 Chascsa DM, Vargas HE. The gastroenterologist's guide to management of the post-liver transplant patient. Am J Gastroenterol 2018;113:819-28. [PMID: 29748558 DOI: 10.1038/s41395-018-0049-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
16 Olmedo-Martín RV, Amo-Trillo V, González-Grande R, Tenorio-González E, Sánchez-García O, de la Cruz-Lombardo J, Rodrigo-López JM, Jiménez-Pérez M. Efficacy and Safety of Anti-TNF-α Agents in Inflammatory Bowel Disease After Liver Transplant: A Case Series. Transplant Proc 2018;50:619-22. [PMID: 29579869 DOI: 10.1016/j.transproceed.2017.09.069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Mccashland TM. Long-term Management of the Liver Transplant Patient. Schiff's Diseases of the Liver 2017. [DOI: 10.1002/9781119251316.ch44] [Reference Citation Analysis]
18 Shaikh SA, Fitzgerald L, Tischer S. Safety and Efficacy of Biologic Agents for the Management of Inflammatory Bowel Disease After Liver Transplantation. Pharmacotherapy 2017;37:1578-85. [PMID: 28960437 DOI: 10.1002/phar.2036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
19 Filipec Kanizaj T, Mijic M. Inflammatory bowel disease in liver transplanted patients. World J Gastroenterol 2017; 23(18): 3214-3227 [PMID: 28566881 DOI: 10.3748/wjg.v23.i18.3214] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
20 Garrouste C, Anglicheau D, Kamar N, Bachelier C, Rivalan J, Pereira B, Caillard S, Aniort J, Gatault P, Soubrier M, Sayegh J, Colosio C, Buisson A, Thervet E, Bouvier N, Heng AE. Anti-TNFα therapy for chronic inflammatory disease in kidney transplant recipients: Clinical outcomes. Medicine (Baltimore) 2016;95:e5108. [PMID: 27741127 DOI: 10.1097/MD.0000000000005108] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
21 Hartery K, O'Reilly S, Houlihan D, Doherty G, Mulcahy H, Cullen G, Sheridan J. Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis. Aliment Pharmacol Ther 2017;45:376-8. [PMID: 27933688 DOI: 10.1111/apt.13861] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
22 Fennimore B, Regner EH, Gerich ME. Primary Sclerosing Cholangitis-Associated Inflammatory Bowel Disease. Primary Sclerosing Cholangitis 2017. [DOI: 10.1007/978-3-319-40908-5_3] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]